# Trevi Therapeutics (TRVI) — Analyst Forecast

TRVI · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/trvi/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 12 | 0 | 0 | 12 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $24.00 | $29.00 | $36.00 | 6 |

Last price $12.11 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 14, 2026 | Jones Trading | Maintained | Buy | $28.00 |
| Aug 7, 2026 | Oppenheimer | Maintained | Outperform | $25.00 |
| Aug 7, 2026 | Cantor Fitzgerald | Maintained | Overweight | $30.00 |
| Jul 21, 2026 | BMO Capital | Initiated Coverage | Outperform | $36.00 |
| Jul 20, 2026 | HC Wainwright & Co. | Maintained | Buy | $24.00 |
| Jul 20, 2026 | B. Riley Securities | Maintained | Buy | $31.00 |
| May 20, 2026 | Needham | Maintained | Buy | $23.00 |
| May 6, 2026 | Needham | Maintained | Buy | $23.00 |
| May 6, 2026 | HC Wainwright & Co. | Maintained | Buy | $21.00 |
| Apr 17, 2026 | D. Boral Capital | Maintained | Buy | $19.00 |
| Mar 19, 2026 | Jones Trading | Maintained | Buy | $24.00 |
| Mar 18, 2026 | Needham | Maintained | Buy | $24.00 |
| Mar 18, 2026 | D. Boral Capital | Maintained | Buy | $19.00 |
| Mar 18, 2026 | Morgan Stanley | Maintained | Overweight | $18.00 |
| Mar 9, 2026 | HC Wainwright & Co. | Maintained | Buy | $21.00 |
| Mar 9, 2026 | D. Boral Capital | Maintained | Buy | $19.00 |
| Jan 9, 2026 | HC Wainwright & Co. | Maintained | Buy | $21.00 |
| Jan 8, 2026 | D. Boral Capital | Maintained | Buy | $19.00 |
| Dec 19, 2025 | Stifel | Maintained | Buy | $18.00 |
| Nov 20, 2025 | Leerink Partners | Maintained | Outperform | $16.00 |

## Frequently Asked Questions

### What is the price target for TRVI stock?

The average 12-month analyst price target for Trevi Therapeutics (TRVI) is $29.00, with a high estimate of $36.00 and a low of $24.00, across 6 analysts.

### Is TRVI a buy, sell, or hold?

Analysts covering Trevi Therapeutics currently average a Buy rating: 12 buy, 0 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for TRVI?

The average price target of $29.00 implies 139.47% upside from the last price of $12.11.

### What is the latest analyst rating on TRVI?

On Aug 14, 2026, Jones Trading maintained Trevi Therapeutics at Buy with a price target of $28.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).